Diagnosis and Management of Acute Coronary Syndrome

Dear Colleagues,

Although substantial progress has been made in the diagnosis and management of acute coronary syndrome (ACS), cardiovascular disease remains the leading cause of death worldwide, mainly due to ACS. Currently, there are a number of topical aspects in the study of ACS. For example, it is known that biomarkers are critical in the diagnosis and treatment of ACS patients. The release of cardiac markers is time-dependent, and an initial negative result does not exclude the presence of myocardial ischemia. Therefore, identification of novel biomarkers with high sensitivity and convenience for ACS diagnosis would improve the outcome of this disease following treatment at earlier stages. Chest pain characteristics, specific associated symptoms, electrocardiogram abnormalities, and the levels of serum biomarkers of myocardial necrosis are essential for a diagnosis of ACS. However, rather than chest pain, some ACS patients present with atypical symptoms, so it is known that one-third of patients with ACS present at the hospital with no chest pain. The implications of absence of chest pain are important in terms of management and prognosis. Management of ACS has emerged as a challenge during the COVID-19 era. There has been a significant increase in the morbidity and mortality associated with ACS both as a direct and an indirect consequence of the pandemic, and therefore, this issue is extremely relevant.

To this end, we welcome submissions on, but not limited to, the following topics:

• Diagnostic or prognostic biomarkers of ACS (focusing on early detection is preferred);
• Diagnostic or prognostic scoring of ACS (focusing on early detection is preferred);
• Management and prognosis of ACS with atypical symptoms;
• ACS and SARS-CoV-2 infection (focusing on management and prognosis is preferred);
• Diagnostic and management aspects in older patients with ACS;
• Coronary artery vasospasm;
• Diagnosis and management of cardiogenic shock complicating ACS;
• Prognostic aspects of invasive and non-invasive therapies for ACS;
• “No-reflow” phenomenon in ACS patients;
• Management and prognosis of ACS with arrhythmias.

Prof. Dr. Konstantin Nikolaev
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• acute coronary syndrome
• biomarkers
• prognostic scoring
• atypical symptoms
• SARS-CoV-2 infection
• invasive and non-invasive therapies